{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:29:07Z","timestamp":1792218547289,"version":"4.4.0"},"reference-count":22,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,11,20]]},"abstract":"<jats:p>A wide variety of cytotoxic medications cause interstitial lung disease (ILD). For the first time, we describe ILD in an 82-year-old woman with muscle invasive bladder cancer 10 days after receiving cetuximab as part of a novel trial. She had no significant medical history or drug allergies, had good exercise tolerance and a 5 pack-year smoking history. She received neoadjuvant chemotherapy (gemcitabine, cisplatin) with a good response on MRI. She was eligible for a phase 2 trial of cetuximab with chemotherapy and radiotherapy for muscle invasive bladder cancer (TUXEDO), in which the trial arm used cetuximab plus standard chemoradiotherapy to the bladder (64 grey in 32 fractions plus mitomycinandfluorouracil). Ten days after her third infusion of cetuximab, she was presented with type 1 respiratory failure. Thoracic CT scan demonstrated new widespread ground glass change in the lungs. She received high-dose steroids (prednisolone 1\u2009mg\/kg), broad spectrum antibacterial cover and non-invasive ventilation. She survived to be discharged with residual respiratory failure.<\/jats:p>","DOI":"10.1136\/bcr-2017-220181","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T23:21:18Z","timestamp":1513812078000},"page":"bcr-2017-220181","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist\u2019s perspective"],"prefix":"10.1136","volume":"2017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-412X","authenticated-orcid":false,"given":"Louise","family":"Price","sequence":"first","affiliation":[{"name":"The Cancer Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK"},{"name":"The Deanesly Centre, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Glynn","sequence":"additional","affiliation":[{"name":"The Cancer Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Zarkar","sequence":"additional","affiliation":[{"name":"The Cancer Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.1","doi-asserted-by":"crossref","first-page":"1284419","DOI":"10.1080\/2331205X.2017.1284419","article-title":"Being aware of potentially fatal interstitial lung disease in patients with head and neck cancer treated with concurrent cetuximab and radiotherapy","volume":"4","author":"Shimada","year":"2017","journal-title":"Cogent Med"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.2","doi-asserted-by":"publisher","DOI":"10.2174\/1874306401206010063"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/resp.12665","article-title":"Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study","volume":"21","author":"Hamada","year":"2016","journal-title":"Respirology"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0344"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.5","unstructured":"Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000558\/WC500029119.pdf"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.6","first-page":"3790","article-title":"Interstitial pneumonitis after using cetuximab in cancer patients","volume":"9","author":"Zhang","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12190-3"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.16.1887"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106106"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.10","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.031039"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.11","unstructured":"British Thoracic Society. BTS interstitial lung disease guideline, 2008."},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.12","unstructured":"National Institute for Health and Clinical Excellence. IPF guideline.\u00a0Idiopathic pulmonary fibrosis in adults: diagnosis and management, 2013."},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6137.602"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-601"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.15","unstructured":"Imclone Systems Incorporated IN. Erbitux (Cetuximab) Package Insert. Bristol-Myers Squibb Co PN, 2008."},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.16","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu128"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-011-0199-0"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.18","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-113"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11523-013-0295-4","article-title":"A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment","volume":"9","author":"Shablak","year":"2014","journal-title":"Target Oncol"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.20","doi-asserted-by":"crossref","unstructured":"Achermann Y , Frauenfelder T , Obrist S , et al . Findings that shed new light on the possible pathogenesis of a disease or an adverse effect A rare but severe pulmonary side effect of cetuximab in two patients. BMJ Case Rep 2012.doi:10.1136\/bcr-03-2012-5973","DOI":"10.1136\/bcr-03-2012-5973"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.21","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2009.n.019"},{"key":"2025082801502811000_2017.dec19_1.bcr-2017-220181.22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med Overseas Ed"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-220181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:50:33Z","timestamp":1756371033000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-220181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":22,"alternative-id":["10.1136\/bcr-2017-220181"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-220181","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,20]]}}}